The initial and significant event developed in ischemic stroke is the sudden decrease in blood flow and oxygen supply to brain tissue, leading to dysfunction of the mitochondria. Many attempts were and are being made to develop new drugs and treatments that will save the ischemic brain, but the efficacy is not optimal and in many patients, irreversible damage to the brain will persist. We review a unique approach to evaluate mitochondrial function and microcirculatory hemodynamic in real time in vivo. Three out of four monitored physiological parameters are integrated into a new Brain Metabolic Score (BMS) calculated in real time and is correlated to Brain Oxygen Balance. The technology was adapted to various experimental as well as clinical situations for monitoring the brain in real time. The developed protocols could be used in testing the efficacy and safety of new drugs in experimental animals. Few models of brain monitoring during partial or complete ischemia were developed and used in naive animals or under brain activation protocols. It was found that mitochondrial function/dysfunction is the major and dominant parameter affecting the calculated Brain Metabolic Score. Using our monitoring system and protocols will provide direct information regarding the ability of the tested brain to provide enough oxygen consumed by the mitochondria in the "resting" or in the "activated" brain in vivo and in real-time. Preliminary studies, indicated that testing the efficacy and safety of new neuroprotectant drugs provided significant results to the R&D studies of ischemic stroke related to mitochondrial function.

中文翻译：

---

缺血性卒中的线粒体功能和脑代谢评分 (BMS)：“神经保护剂”安全性和有效性的评估

缺血性中风的最初和重要事件是脑组织的血流量和氧气供应突然减少，导致线粒体功能障碍。曾经和正在尝试开发新的药物和治疗方法来挽救缺血的大脑，但效果并不理想，而且在许多患者中，对大脑的不可逆损伤将持续存在。我们回顾了一种在体内实时评估线粒体功能和微循环血流动力学的独特方法。四分之三的监测生理参数被整合到实时计算的新脑代谢评分 (BMS) 中，并与脑氧平衡相关联。该技术适用于各种实验和临床情况，用于实时监测大脑。开发的方案可用于测试新药在实验动物中的有效性和安全性。部分或完全缺血期间的大脑监测模型很少被开发并用于幼稚动物或在大脑激活协议下。发现线粒体功能/功能障碍是影响计算的脑代谢评分的主要和主导参数。使用我们的监测系统和协议将提供有关被测大脑在体内和实时提供线粒体在“休息”或“激活”大脑中消耗的足够氧气的能力的直接信息。初步研究表明，测试新型神经保护药物的有效性和安全性，为与线粒体功能相关的缺血性脑卒中的研发研究提供了重要结果。